Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Phase 2 Completed 53 enrolled University of Colorado, Denver Rocky Mountain MS Research Group, LLC · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple sclerosis (RMS).

Timeline

Start: 2012-02
Primary completion: 2015-05
Completion: 2015-05

Publications

Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Feb 12;92(7):e723-e732. doi: 10.1212/WNL.0000000000006916. Epub 2019 Jan 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	1000 mg	Intravenous
Background	Glatiramer Acetate	Small molecule	20 mg	Subcutaneous

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

Summary

Timeline

Publications

Drugs

Indications